

The *voice* of the community pharmacist.



Need-to-Knows for Administering COVID-19 Vaccines

December 10, 2020 | 8 p.m. ET

NCPA Staff Members



Breaking News!



Pfizer/BioNTech vaccine recommended for emergency use authorization











OPERATION WARP SPEED VACCINE DELIVERY MILESTONES

AUTHORIZATION - APPROVAL



Phase 3 Trials

Randomized, double-blind, placebo-controlled studies with more than 30k participants each, including diverse populations, providing rapid data collection



Data Safety Monitoring Board

Independent board evaluates data from ongoing Phase 3 trial, advises manufacturer whether pre-specified success criteria is met



Emergency Use Authorization (EUA)

Granted by the FDA following a recommendation by the Vaccines and Related Biological Products Advisory Committee and an independent analysis of drug manufacturing facilities, processes and drug product data

Biologics Licensure Application (BLA)

Includes safety and efficacy data along with product, manufacturing and clinical studies information to consider full approval, potentially following six months of additional monitoring

PRIORITIZATION - ALLOCATION



National Academies of Science, Engineering and Medicine

Informs the CDC Advisory Committee on Immunization Practices (ACIP) on which populations receive priority for vaccines



Vaccine Priority

ACIP recommends vaccine priority to the CDC director, who reviews and recommends to the HHS Secretary



HHS Secretary

Endorses recommendation and staffs policy for approval to National Security Council



Allocation

Distribution based on census data for prioritized groups; drives the delivery of available doses to states, tribes, territories, localities and federal agencies



Jurisdictions/Federal Agencies

Execute federal priority guidance to identify points for vaccine delivery and administration



Delivery

Begins 24 hours after EUA, first doses available within 96 hours

DISTRIBUTION - ADMINISTRATION

Initial dose administered at various locations:



MANUFACTURERS Produce products



SUPPLIES Needles, syringes, alcohol swabs, etc.



KITTING Preassembles and packages in ready-to-ship kits



DISTRIBUTOR
Delivers vaccine and
supplies to administration sites

Administration sites

- PharmacyPublic health clinic
- Long term care facility
- Hospital
- Federally qualified health center
- Healthcare provider (doctors' office)
 Mass vaccination site
- Indian Health Service
- Home health
- Mobile siteOther federal sites



Data IT/Systems

Jurisdictions provide dosing information to CDC data clearing house through immunization information systems and partner systems: patient data is de-identified with no personal identifying or health information



Second Dose Tracking

As most vaccines require two doses – 21 to 28 days apart from the same manufacturer, second dose reminders will be generated through existing IT systems



Pharmacovigilance

Post-vaccination monitoring continues for 24 months to detect, assess, understand, and prevent adverse effects: coordinated with vaccine companies, the CDC and FDA through multiple vaccine safety systems and V-SAFE



Work Group Proposed Interim Phase 1 Sequence

Phase1c
Adults with high -risk medical conditions
Adults 65+

Phase 1b Essential workers

(examples: Education Sector, Food & Agriculture, Utilities, Police, Firefighters, Corrections Officers, Transportation)

Phase 1a Health care personnel LTCF residents

Time





Billing: Medicare

- Pharmacist needs Type 1 NPI to order (prescribe) vaccine reimbursed by Medicare
 - National Plan and Provider Enumeration System (NPPES)
- Pharmacy needs to be enrolled as a Pharmacy or Mass Immunizer
 - Use pharmacy's existing Type 2 NPI
 - Provider Enrollment, Chain, and Ownership System (PECOS)
- Medical billing intermediary needed
 - FDS, OmniSys, Change Healthcare, EBS
- \$28.39 to administer single-dose vaccines.
- \$16.94, and \$28.39 for the administration of the initial dose(s) and final dose, respectively in the series.



Billing: Medicaid

- Reimbursement pathway and vaccine administration rates will vary state to state
- Claims could be covered on prescription benefit, the medical benefit, or both.
- If both pathways are available to the pharmacy, review vaccine administration reimbursement rates and make sure staff know which is preferred. Transaction fees and real-time adjudication may be factors in addition to the vaccine administration fee.
- All Medicaid programs, fee for service and managed care, are required to cover COVID vaccinations.





Billing: Commercial

- Out-of-network vaccine providers must be reimbursed.
- NOW is the time to check on enrollment for employer plans in your area that have limited networks.
- Claims could be covered on prescription benefit, the medical benefit, or both.
- If both pathways are available to the pharmacy, review vaccine administration reimbursement rates and make sure staff know which is preferred. Transaction fees and real-time adjudication may be factors in addition to the vaccine administration fee.





Billing: Uninsured

- COVID-19 vaccine providers can claim reimbursement for administering the vaccine to uninsured patients through a program overseen by HRSA
 - NOW is the time to sign up with Optum Pay (different from Optum Rx)
 if you plan to submit claims for this program.
 - HRSA has contracted with UnitedHealth Group to be the sole administrator of the Uninsured Program for COVID-19.

www.hrsa.gov/coviduninsuredclaim





Billing: Codes

- CPT Codes* Talk to your medical billing intermediary about submitting claims for Medicare Part B and health plan medical benefits.
 - a. Pfizer product: 91300, first dose: 0001A, second dose: 0002A
 - b. Moderna product: 91301, first dose 0011A, second dose: 0012A
- NCPDP The guidance from NCPDP is not a mandate for PBMs, but many may implement the recommendations as published.
 - a. One-dose COVID-19 vaccine: Use the actual liquid volume (e.g. 0.5 mL) for the Quantity Dispensed, a Days Supply of "1", Professional Service Code "MA", and Ingredient Cost of \$0.00 or \$0.01 (depending on the payer).
 - b. Two-dose COVID-19 vaccine: Use the actual liquid volume (e.g. 0.5 mL) for the Quantity Dispensed, a Days Supply of "1", Professional Service Code "MA", Ingredient Cost of \$0.00 or \$0.01 (depending on the payer), and the appropriate SCC indicating which dose in the series as follows:
 - i. Initial Dose use SCC of 2 "Other Override"
 - ii. Final Dose use SCC of 6 "Starter Dose"






Advocacy

- CMS prohibit patient steering by PBMs in regards to vaccine administration
- No differential payment based on vertical integration and PBM/pharmacy business agreements
- Need payment parity and pharmacy choice for success




Vaccine Kits





VaccineFinder







About VAERS	Report an Adverse Event	VAERS Data 🗸	Resc	ources v	Submit Follow-Up Informa	ation		
Completion Status	Report an Adverse E	Report an Adverse Event - Patient Information Instructions en Españ						
Patient Information	Note: Fields marked with	Note : Fields marked with an * are essential and should be completed.						
Reporter Information	Item 1 🕢	Item 1 🕢						
Facility Information	Patient first name:	Patient first name:			Patient last name:			
Vaccine Information								
Additional Information	Street address:	Street address:						
VAERS								
Patient Information	City:	City: State:		County:				
	7: der		e	~	Fil-			
respectors stress manual	Zip code:	Phone:			Email:			
Facility Information	Item 2 😯			Item 3 😯				
Vaccine Information		hann or manhanni		* Sex:				
Additional Information	mm/dd/yyyy	* Date of birth (✓ mm/dd/yyyy or ☐ mm/yyyy) mm/dd/yyyy		○ Male ○ Female ○ Unknown				
	Item 4 😯							
Click to preview VAERS form		* Date of vaccination (mm/dd/yyyy or mm/yyyy)			Time:			
	mm/dd/yyyy			hh:mm O AM O PM				
	Item 5 😯							



V-SAFE

Vaccine safety assessment for essential workers (V-SAFE)



 Text messages or email from CDC with follow-up – daily 1st week post-vaccination and weekly thereafter out to 6 weeks



2. Any clinically important event(s) reported by vaccinated person

Healthcare workers, essential workers, etc.

VAERS call center



3. Follow-up on clinically important event, complete a VAERS report if appropriate









IMPORTANT RESOURCES

- NCPA's Coronavirus Resource Center <u>https://ncpa.org/covid-testing</u>
- CPESN COVID-19 Best Practices https://www.covidbestpractices.com/
- CDC Info for Healthcare Professionals about COVID-19 https://www.cdc.gov/coronavirus/2019-nCoV/hcp/index.html
- Medicare Provider Enrollment (PECOS)
 https://pecos.cms.hhs.gov/pecos/login.do#headingLv1
- VaccineFinder Registration https://locating.health/register
- VAERS https://vaers.hhs.gov/esub/index.jsp



Questions?





SAVE THE DATE

- CMS is hosting a call for members on Medicare Provider Enrollment to bill for vaccines
 - Tuesday, Dec. 15, at 1:30 p.m. ET.
 - To participate, just call **877-256-8277**. No meeting ID or passcode is required.
- An Update for Managing Personnel in the Time of COVID-19
 - Thursday, Dec. 17, at 8 p.m. ET
 - Registration: https://register.gotowebinar.com/register/4743468396106057744
- Missed a COVID-19 related webinar?
 - https://ncpa.org/coronavirus-information#webinars





The *voice* of the community pharmacist.

www.ncpa.org

Follow us on social media



